Cabaletta Bio, Inc. (CABA) Investor Relations Documents

Cabaletta Bio, Inc. (CABA) investor relations documents from the company's IR site: 2 presentations, 38 press releases; latest deck 2026-08-12. Read in-app with summaries. First-party data.

Presentation: Cabaletta Bio's rese-cel therapy aims to cure autoimmune diseases with a single infusion, targeting a BLA filing for Myositis in 2H27.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-13Press releaseCabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-13Press releaseCabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-12PresentationPresentation
2026-06-03Press releaseCabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Ear
2026-06-03Press releaseCabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Ear
2026-05-14Press releaseCabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-14Press releaseCabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at
2026-05-14Press releaseCabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-14Press releaseCabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at
2026-05-14PresentationCorporate Presentation
2026-05-14Press releasePDF
2026-05-04Press releaseCabaletta Bio Announces Pricing of $150 Million Underwritten Offering
2026-05-04Press releaseCabaletta Bio Announces Pricing of $150 Million Underwritten Offering
2026-04-28Press releaseCabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel
2026-04-28Press releaseCabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel
2026-04-27Press releaseCabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel
2026-04-27Press releaseCabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel
2026-03-23Press releaseCabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2026-03-23Press releasePDF: Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2026-03-23Press releaseCabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2026-02-24Press releaseCabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference
2026-02-24Press releaseCabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference
2026-02-05Press releaseCabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
2026-02-05Press releaseCabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
2026-01-12Press releaseCabaletta Bio Announces 2026 Strategic Priorities
2026-01-12Press releaseCabaletta Bio Announces 2026 Strategic Priorities
2025-11-10Press releaseEarnings Release
2025-03-31Press releaseEarnings Release
2025-03-31Press releaseCabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
2025-03-31Press releasePDF: Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
2024-11-14Press releaseEarnings Release
2024-11-14Press releaseCabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
2024-11-14Press releasePDF: Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
2024-08-08Press releaseEarnings Release
2024-08-08Press releaseCabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
2024-08-08Press releasePDF: Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
2024-05-15Press releaseEarnings Release
2024-05-15Press releaseCabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
2024-03-21Press releaseEarnings Release
2024-03-21Press releaseCabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

CABA overview · CABA earnings · CABA financials · CABA KPIs · CABA ownership · CABA peers · CABA filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.